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Chapter 1: Abstract 
Alpha-1 antitrypsin (AAT) deficiency is a genetic disease that can affect both the lung and 
the liver. The vast majority of patients harbor a mutation in the SERPINA1 gene resulting 
in a single substitution from glutamic acid to lysine at amino acid position 342 (p.E342K). 
The AAT encoded by the Z allele (ATZ) is not properly folded and accumulates in the 
endoplasmic reticulum (ER) of hepatocytes resulting in liver disease through a gain of 
function mechanism. The liver disease is a prototype of conformational disorder due to 
protein misfolding and aggregation. Intracellular retention of ATZ triggers a complex 
injury cascade including autophagy, ER-stress and other mechanisms. Nevertheless, 
several aspects of the disease pathogenesis are still unclear.  
I found that ATZ induces activation of c-JUN N-terminal kinase (JNK) and c-JUN 
signaling in livers of a mouse model (PiZ mice) of the disease. JNK activation was 
confirmed in human livers of patients homozygous for the Z allele with severe liver disease 
requiring hepatic transplantation. In mice, genetic ablation of Jnk1 or Jnk2 decreased ATZ 
levels by reducing c-JUN mediated SERPINA1 expression. Moreover, I have found up-
regulation of genes associated with response to ER stress in PiZ mouse livers by 
expression array profiling. Among the differentially expressed genes, I focused on the 
CCAAT/Enhancer-Binding Protein Homologous Protein (Chop) that was significantly up-
regulated in both mouse and human livers expressing ATZ. To investigate the role of 
CHOP in ATZ-induced liver damage, I crossed PiZ with Chop null (Chop-/-) mice. Genetic 
ablation of Chop resulted in a marked reduction of hepatic ATZ levels in juvenile PiZ 
mice. SERPINA1 mRNA levels in livers of PiZ/Chop-/- mice were also significantly 
reduced compared to PiZ controls, suggesting that CHOP induces ATZ accumulation by 
increasing SERPINA1 transcription. CHOP was indeed found to up-regulate SERPINA1 
expression through binding with C/EBPβ and c-JUN on SERPINA1 regulatory elements. 
So far, JNK and CHOP have been involved in the pathogenesis of several liver disorders 
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but not in hepatic disease induced by ATZ. The results of my studies show that JNK and 
CHOP are important players in the disease pathogenesis and are novel therapeutic targets.  
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Chapter 2: Introduction 
2.1 Alpha-1 antitrypsin deficiency  
Alpha1-antitrypsin (AAT) deficiency (AATD, OMIM #613490) is an inherited 
disorder that may result in lung and liver disease [1]. It was described for the first time in 
1963 by Laurell and Eriksson which observed the lack of alpha-1 band on serum protein 
electrophoresis of individuals with severe obstructive lung disease [2]. The association 
with liver disease was reported in the 1969 by Sharp and colleagues who observed familial 
infantile liver cirrhosis in patients with AATD [3]. The disorder is inherited by 
an autosomal codominant pattern and affects about 1 in 2,000-3,000 live births [4, 5]. 
However, the prevalence varies among populations with higher frequency in individuals of 
European ancestry and lower frequency in people of Asian descent [6]. Nevertheless, 
AATD is largely under diagnosed and exact prevalence in most populations remains 
unknown [7]. 
 
2.1.1 Clinical manifestations 
Signs and symptoms of the disease and their onset vary among individuals. The 
most frequently affected organs are lung and liver, while the skin is less frequently 
involved. Patients with AATD develop the first signs and symptoms of lung disease 
between the third and fourth decades of life [8]. The classic symptoms at the onset are 
shortness of breath following mild physical activity, wheezing, and increased risk of lung 
infections [8]. Affected individuals often develop chronic obstructive pulmonary disease 
(COPD) and panlobular lung emphysema [9]. Moreover, the lung of subjects with AATD 
showed an increased inflammation, associated to increased neutrophils and cytokines 
levels (especially leukotriene B4; LTB4) [10, 11]. Smoking or exposure to tobacco smoke 
accelerates the damage to the lungs and the onset of emphysema. In addition to increasing 
the inflammatory reaction in the respiratory tract, cigarette smoke directly inactivates AAT 
by oxidizing essential methionine residues to sulfoxide forms, and thus decreasing the 
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enzyme activity [12]. Other symptoms may include chronic bronchitis or bronchiectasis 
[13]. 
The spectrum of liver disease varies enormously and it includes asymptomatic 
states, acute liver failure, fibrosis, cirrhosis and increased risk of developing hepatocellular 
carcinoma (HCC) [14]. Liver biopsy findings in both children and adult patients may 
include steatosis and lobular inflammation. Analysis of a unique cohort of homozygotes 
identified by an unbiased newborn screening performed in Sweden has shown that about 
8% of homozygotes develop clinically significant liver disease in the first four decades of 
life [15, 16], indicating that genetic and/or environmental modifiers play a major role in 
susceptibility to liver disease. So far, a single nucleotide polymorphism that suppresses the 
translation of a protein involved in ER-associated degradation pathway (ERAD), ERManI, 
was found to accelerate the onset of end-stage liver disease [17]. Clinical data indicate that 
there are two pick ages for severe AATD-associated liver disease to present: birth to 5 and 
50-65 years of age [18]. Moreover, the human disease has different features in infants 
compared to adults. These differences suggest that pathogenic mechanisms vary depending 
on the age and more powerful modifiers play a role in the liver disease in children. 
In rare cases, patients affected by AATD develop a skin condition named as panniculitis 
[19], presenting with painful, weepy cutaneous nodules that can sometimes undergo to 
necrosis. Vasculitis is another of the rare skin manifestations associated to AATD [20]. 
Measurement of serum AAT concentration is the first step in the diagnosis of 
AATD. A reduction of 50% of the lower limit of the normal range in serum levels of AAT 
is considered an evidence for AATD. However, AAT levels can increase several folds in 
response to different conditions, thus making difficult to detect its deficiency [21]. A more 
definitive and specific diagnostic method is the genotype analysis by polymerase chain 
reaction (PCR) and sequencing of the PCR products. Nevertheless, many individuals 
with AATD are likely undiagnosed [7] because several affected subjects are asymptomatic 
or have delayed onset of symptoms. Thus, the diagnostic tests should be performed for all 
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patients with liver disease of unexplained etiology and those with COPD and asthma 
showing resistance to medical therapy. Moreover, once an index case has been diagnosed, 
it is strongly recommended to test all at the risk relatives. 
 
2.1.2 Genetics and polymorphisms of SERPINA1 
AAT is encoded by SERPINA1 gene, also known as the protease inhibitor (Pi). 
Mutations in the SERPINA1 gene can cause AATD. So far, more than 100 variants have 
been identified and the different AAT variants are distinguishable by isoelectric focusing 
[22]. The migration phenotype of mature, glycosylated wild type protein was denoted M, 
and homozygotes classified as PiMM. Other variants that migrate slower or faster are 
termed A-L and N-Z, depending on whether they run proximal or distal to the M band. The 
most common severe deficiency variant migrates the slowest and is named Z [23]. Some of 
these variants do not affect production of AAT while others cause deficiency of the protein 
with clinically significant effects. On the basis of plasma levels and function of AAT, 
variants are classified as normal, deficient, null and dysfunctional. Thus, the levels of AAT 
in the serum depend on the genotype. In circulating plasma of normal PiMM subjects, 
AAT concentration is in the range of 20-50 µM. Deficient alleles are associated with lower 
plasma AAT levels. The most common deficiency variant is produced by Z allele 
(p.E342K) followed by the S allele (p.E264V). Individuals homozygous for the S allele 
(PiSS) have a mild reduction in serum AAT levels whereas PiZZ subjects with two copies 
of the Z allele (ZZ) in each cell have a severe reduction in serum AAT levels, which are 
decreased to 10-15% of the normal levels. Those with the SZ combination have an 
increased risk of developing lung diseases (such as emphysema), particularly if they 
smoke. Individuals with an MS combination usually produce enough AAT to protect their 
lungs. People with MZ alleles, however, have a slightly increased risk of impaired lung or 
liver functions. The dysfunctional variants, such as the Pittsburgh variant (p.M358R) [24], 
have altered protein function and are synthesized in normal quantities. These variants lead 
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to reduced anti-proteases inhibition and are thus associated with lung disease. The null 
alleles, like the null-Hong Kong allele [25], produce no detectable AAT protein in the 
plasma and are associated with only lung disease but not the liver disease and high risk to 
develop COPD.  
 
2.1.3 AAT: gene regulation, structure and function of the protein  
SERPINA1 gene is approximately 12.2 Kb in size on chromosome 14q32.13 [26] and is 
composed by seven exons and six introns. First three exons are transcriptionally alternative 
and termed as 1A, 1B, and 1C [27]. Different tissue-specific isoforms are generated mainly 
by the usage of different transcription starting sites (TSS) and also through alternative 
splicing, thus reflecting the important of 5’untranslated region (UTR) in the regulation of 
SERPINA1 expression. The hepatic TSS is located within the exon 1C while the TSS in 
monocytes is positioned in the exon 1A [28]. The Exon 2 contains the translational starting 
site for all the isoforms, producing a protein of 418 amino acids, including a 24 amino 
acids signal sequence. The regulation of the gene expression is mainly transcriptional and 
tissue-specific. Trans-acting factors, including Hepatocyte nuclear factors 1 (HNF1) and 3 
(HNF3), are able to bind SERPINA1 promoter and thereby, they contribute to its 
expression in the liver [29]. In addition, SERPINA1 gene has enhancer regulatory regions 
located at 5’UTR that contains putative binding sites for the Activator protein 1 (AP-1) 
family of transcription factors (including members of JUN, FOS and ATF families) and the 
CCAAT Enhancer Binding Protein Beta (C/EBPβ) [30].  
AAT is an acute phase protein and its blood levels typically increase by 2- to 4-
folds during inflammatory responses [31]. Moreover, expression of SERPINA1 is 
controlled by several cytokines such as interleukin 6 (IL6), interleukin 1β (IL1β), 
oncostatin M (OSM), and tumor necrosis factor-α (TNFα) [32]. 
AAT is a 52-kDa glycoprotein synthesized mainly by hepatocytes in the liver [33, 34]. 
However, other cell types can produce AAT, including lung and gut epithelial cells [35-
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37], neutrophils [38], and alveolar macrophages [39]. During its synthesis, AAT is targeted 
to the endoplasmic reticulum (ER) to be folded and glycosylated at three distinct 
asparagine residues (amino acid residues 46, 83, and 247). The protein is further processed 
in the Golgi and, then, secreted into the blood.  
AAT is a serine protease inhibitor protein and its key function is to inhibit 
neutrophil elastase (NE) within the lung [40]. During infections, NE is released from white 
blood cells to fight infections, but it can also attack normal tissues (especially the lungs) if 
not tightly controlled by anti-proteases such as AAT. In addition to NE, AAT can also 
inhibit other proteases such as trypsin, cathepsin G, and proteinase 3 [41]. AAT shares 
both structural and functional characteristics with other members of the serpin family 
including alpha-1 anti-chymotrypsin, protein C inhibitor, and anti-thrombin III. It is 
composed by three beta-sheets (named from A to C) and nine alpha-helices (named from A 
to I). The active site is located at the amino acids Met358-Ser359, which are part of a 
reactive center loop. Upon binding, serine proteases cleave the Met358-Ser359 bond 
releasing potential energy and resulting in a conformational change leading to protease 
distortion and inactivation. The resulting AAT-protease complex is then recognized by 
hepatic receptors and removed from circulation [42].  
AAT has also anti-inflammatory and immunomodulatory functions. For example, 
AAT reduces neutrophil chemotaxis [43], inhibits TNFα and cytokines release from 
monocytes and neutrophils in response to endotoxin [44-47].  
 
2.1.4 Pathobiology of AATD 
Different mutations in the SERPINA1 gene have been described. However, most of 
patients with AATD (about 95%) are homozygous for the Z allele, which is a single amino 
acid substitution at position 342 changing glutamic acid into lysine (p.E342K). This 
mutation alters protein folding and causes polymerization of  mutant Z alpha-1 antitrypsin 
(referred as ATZ) in the endoplasmic reticulum (ER) [48]. In PiZZ individuals 
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homozygous for the Z allele, AAT levels in the serum are less than 15% of normal, due to 
its retention in the ER. The low circulating levels of AAT lead to an inadequate anti-
protease protection in the lower respiratory tract that might lead to progressive lung 
emphysema. PiZZ individuals are also at risk of developing liver disease due to 
intracellular retention and accumulation of aberrantly folded and proteotoxic ATZ in 
hepatocytes that might lead to hepatitis, fibrosis, cirrhosis, liver failure, and HCC [49]. 
Therefore, the lung disease is caused by a loss of AAT function while the liver disease is 
due a gain of function mechanism.  
The pathogenesis of HCC due to accumulation of ATZ is still poorly understood. 
One possible mechanistic explanation arises from the evidence that only a proportion of 
hepatocytes have intracellular ATZ globules in the livers of PiZZ patients. This 
observation suggests that globule-containing hepatocytes can produce regenerative signals 
acting on globule-devoid hepatocytes which in turn acquire a proliferative advantage and 
can develop cancer [50]. However, this hypothesis has to be confirmed and signaling 
pathways involved in cancer onset and progression have not been yet identified.  
 
2.1.5 Mechanism of ATZ polymerization 
Misfolding and polymerization are central features in the pathogenesis of AATD. 
Several pathogenic variants of AAT were found to cause intracellular polymerization and 
plasma deficiency. In addition, mutations in other members of the serpin family also 
resulted in protein aggregation, e.g. thrombosis due to anti-thrombin aggregation, 
angioedema due to aggregation of C1 inhibitor and encephalopathy due to neuroserpin 
aggregation. Because a common mechanism is involved in polymerization of these 
different proteins, these diseases are also defined as serpinophaties [51]. Understanding of 
the structural mechanism responsible for ATZ polymerization is therefore important to 
prevent AATD and possibly other disorders. 
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Different models of AAT polymerization have been proposed and they are based on 
different conditions giving rise to structurally and dynamically different polymer species. 
According to the first model proposed by Lomas and colleagues in 1992 and known as 
“single-strand linkage”, the polymerization occurs through  linkage by the incorporation of 
a portion of the reactive central loop (RCL) of one monomer into the β-sheet A of another 
monomer [48]. This model was supported by the evidence that exogenous RCL peptides 
block polymerization. However, two alternative models have also been proposed. One 
model known as “β-harpin linkage” is based on crystal structure of a dimer of anti-
thrombin in which the intermolecular linkage included the insertion of two long β-strands 
(s4A and s5A) of one molecule into β-sheet A of another [52]. The last model, known as 
“triple-strand linkage”, was extrapolated by the crystal structure of a self-terminating 
trimer of AAT [53]. The intermolecular linkage consists of the three C-terminal β-strands 
of AAT. Self-terminating trimer is recognized by the 2C1 antibody, which recognizes 
polymers from the liver of subjects affected by AATD [54]. These data suggest that single 
and/or triple-strand linkage may induce disease-relevant polymerization. 
 
2.1.6 Intracellular processing of ATZ  
Disposal of proteotoxic ATZ is mediated by two major pathways: ubiquitin 
proteasome system (UPS) and autophagy. It has been estimated in vitro that approximately 
70% of ATZ is degraded by the proteasome through the ER-associated degradation 
(ERAD) pathway, 15% is normally secreted into the blood while the remaining 15% forms 
polymers within the ER. ATZ polymers are in part degraded by autophagy, but a 
proportion persists in insoluble inclusions [55].  
The ER-associated degradation (ERAD) pathway is a highly conserved process by 
which folding-defective proteins are selected and ultimately degraded by the proteasome. 
The ERAD substrates are recognized in the ER and then ubiquitinated and dislocated from 
ER to the cytosol for proteasome degradation. Currently, the complex involved in the 
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dislocation of proteins from the ER to the cytosol remains unkown. Several candidates 
have been suggested including the Derlins (Derlin 1-3), Sec61, and the E3 ubiquint ligase 
HRD1 [56]. Recent studies showed that HRD1 is involved in the dislocation of both null 
Hong Kong variant and ATZ leading to their degradation in the cytosol by proteasome [57, 
58].  
Autophagy is a ubiquitous catabolic process by which cells digest their internal 
constituent to generate amino acids in response to nutrient starvation and other stimuli. It is 
characterized by the formation of double-membrane vesicles in the cytoplasm, which 
sequester cytoplasm and subcellular organelles and then fuse with lysosomes for 
degradation of its contents [59]. The autophagic pathway has been shown to play a crucial 
role in the degradation of aggregated proteins, and defects in autophagy have been 
implicated in the pathogenesis of several degenerative diseases [60]. Autophagy was first 
implicated in AATD when abundant autophagosomes were observed in mammalian cells 
expressing ATZ, in livers of PiZ mice and in livers of patients with AATD [61]. Further 
evidence for the role of autophagy in disposal of ATZ was provided by in vitro studies 
showing delayed degradation of ATZ in mammalian cell lines and in yeast strains with 
deficient autophagy [62, 63]. Studies in a mouse model engineered to express ATZ under 
the control of a liver specific and inducible promoter showed that accumulation of ATZ is 
sufficient to activate autophagy [62]. In yeast which are autophagy-deficient by a mutation 
in ATG6 (beclin 1 in mammals), ATZ disposal is only impaired at high levels of 
expression  [63]. Recent evidences showed that a novel ER-to-lysosome-associated 
degradation (ERLAD) pathway different from canonical autophagy could be responsible 
for degradation of proteasome‐resistant polymers of ATZ. According to this model, 
degradation of ATZ occurs via receptor-mediated vesicular transport [64]. 
Taken together, these results suggest that the ERAD/proteasomal pathway can 
handle ATZ at lower levels of expression, presumably because it is capable of degrading 
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soluble forms of ATZ, but when the expression is higher and ATZ accumulates in 
polymers and insoluble aggregates, autophagy becomes critical for ATZ degradation.  
 
2.1.7 Pathways affected by ATZ in the liver 
Several signaling pathways are specifically activated in response to intracellular 
ATZ accumulation in the ER. Such responses are relevant because they could potentially 
aggravate or protect from the liver damage induced by ATZ. Notably, in cell lines ATZ 
induces activation of B cell receptor associated protein 31 (BAP31), involved in ER quality 
control, and the nuclear factor κb (NFκB) [65]. Activation of NFκB has important 
implications because it mediates inflammation in the liver. Furthermore, NFκB plays a role 
in the liver carcinogenesis [66]. Moreover, ATZ accumulation results in caspase activation 
and mitochondrial injury [67] and induces accumulation of polyubiquitinated conjugates 
like in other disorders with protein aggregation [68].  
Although its role in the pathogenesis of AATD has been suspected, the involvement 
of the unfolded protein response (UPR) remains still controversial. Terminally truncated 
variants of AAT (e.g. Null-Hong Kong and Saar AAT) constitutively activate the UPR [69, 
70]. In contrast, misfolded ATZ in both cell lines and transgenic mice does not activate the 
UPR, even if this pathway is still functional [65, 70]. However, evidences supporting 
activation of the UPR have been generated in human lung epithelial and liver cells from 
PiZZ patients [71, 72] and in different cell lines by association of ATZ with chaperones, 
including binding immunoglobulin protein (BiP) [73].  
Recently, our group reported that intrahepatic accumulation of ATZ has broad 
effects on metabolic liver functions, by affecting liver zonation, HNF4α and β-catenin 
signaling [74].  
In summary, although several pathways have been shown to affect AATD-related 
liver disease, the mechanisms underlying hepatocyte damage and the increase risk of 
cirrhosis and HCC due to ATZ are not completely understood.  
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In this PhD thesis I investigated pathways involved in the pathogenesis of liver 
disease due to ATZ with the goal of identifying therapeutic targets for treatment of the 
AATD-related liver disease.  
 
2.1.8 Therapeutic treatment approaches 
Prevention of both lung and liver diseases is extremely important in AATD 
patients. Avoiding cigarette smoking and alcohol intake are extremely important to prevent 
or delay the development of lung and liver diseases. The mainstay of treatment for severe 
AATD is the AAT augmentation (replacement) therapy, that is the only specific non-
invasive treatment for AATD able to correct the anti-elastase deficiency [75]. However, 
AAT augmentation therapy has no effect on the liver disease. AAT has been purified from 
the plasma of healthy individuals and delivered intravenously to patients at the dose of 
60mg/kg body weight on a weekly basis. This treatment raises levels of serum AAT above 
the threshold of 11µmol/L that is considered to be protective [76]. Augmentation therapy 
indeed results in reduction of the frequency of respiratory tract infections and a decline in 
markers of inflammation. Alternative route of administration have also been investigated. 
Delivery by inhalation was found to be effective. Moreover, several recombinant forms of 
AAT (rAAT) are being developed although none of such recombinant proteins have yet 
approved for human use. In addition, these recombinant proteins are cleared rapidly from 
the circulation likely because they have different glycosylation patterns compared to the 
AAT made by the human liver, affecting their blood half-life [77, 78].  
Gene therapy has also been investigated for the treatment of lung disease of AATD. 
This approach is based on gene transfer of AAT to muscle cells by multiple intramuscular 
injections and it has been investigated in clinical trials [79-81]. Although the injections 
were well tolerated by patients and no serious adverse events were reported, these clinical 
trials failed to show blood levels of AAT above the protective threshold of 11 µM [79-81]. 
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Because this approach is based on ectopic expression of AAT by muscle cells, it does not 
address the liver disease of AATD. 
So far protein augmentation therapy represents the only approved therapy for 
AATD and lung transplantation is the only available option for subjects with severe 
airflow obstruction and emphysema.  
Currently, there are no drug-based therapies for the liver disease. As mentioned 
earlier protein augmentation has no effect on the liver disease that is due a gain of function 
mechanism. Severely affected can only be treated with orthotropic liver transplantation. 
However, we and others believe that a deep understanding of the mechanism underlying 
the disease pathogenesis have potential to unravel novel and more specific druggable 
targets. One strategy is to increase disposal of ATZ by stimulating autophagy using small 
molecules (e.g., carbamazepine and rapamycin) [82, 83] or gene transfer of the autophagy 
regulator transcription factor EB (TFEB) [84]. These approaches have been investigated at 
the preclinical level in a mouse model of AATD and have shown promising results in 
terms of reduction of intracellular ATZ and reduced hepatic fibrosis. One of such studies 
has been translated into a clinical trial investigating the efficacy of carbamazepine in 
patients with severe liver disease (ClinicalTrials.gov Identifier: NCT01379469). 
Other approaches aim to block intracellular ATZ polymerization or to increase the 
folding and the secretion of the mutant ATZ by using small molecules and molecular 
chaperones [85-88]. In addition, RNA interference (RNAi)-based approaches to silence 
ATZ expression in the hepatocytes have been investigated in preclinical models and in 
clinical trials [89, 90]. Although these therapeutic approaches showed promising results in 
mice and non-human primates at reducing ATZ levels and preventing liver fibrosis, they 
are currently on hold because of potential safety concerns [91]. In conclusion, liver disease 
due to ATZ is still lacking non-invaside therapies and their development is urgently 
needed. 
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Chapter 3: Materials and methods 
3.1 Mouse studies  
Mouse procedures were performed in accordance to regulations of the Italian 
Ministry of Health. PiZ transgenic mice [92] were maintained on a C57BL/6 background. 
Jnk1-/- [93], Jnk2-/- [94], and Chop-/- [95] mice were purchased from Jackson laboratory and 
bred with PiZ mice. As positive controls of CHOP activation, C57BL/6 (Charles River 
Laboratories) mice were treated with DMSO (Sigma) or Tunicamycin (Sigma) 4 µg/g for 
24 hours by intra-peritoneal injection. Tunicamycin is a small molecule which inhibits N-
linked glycosylation leading to endoplasmic reticulum (ER)-stress and activation of 
CHOP. As positive controls of TUNEL staining, C57BL/6 (Charles River Laboratories) 
mice were treated with 5 μg/g of body weight of CD95-activating antibody for 6 hours. 
CD95 is a cell death receptor of the TNFR superfamily that induces apoptosis. 
rAAV8pCB-mir914-GFP and rAAV8pCB-GFP were generated, purified, and tittered by 
the UMass Gene Therapy Vector Core as previously described [96]. Vectors were diluted 
in saline solution and intravenously injected in 4-week-old PiZ mice at the dose of 1x1013 
genome copies (gc)/Kg. Only male mice were used for all experiments. Blood samples 
were collected by retro-orbital bleedings and were analyzed for alanine aminotransferase 
(ALT) levels by fluorometric assay kit (Biovision) according to manufacturer’s 
instructions using 1 µL of mouse serum, for each well, diluted in the buffer provided by 
the kit. 
 
3.2 Liver staining and analyses 
For immunofluorescence and histological analysis, liver specimens were fixed in 
4% paraformaldehyde (PFA) overnight at 4°C. After three washes with phosphate-buffered 
saline (PBS), samples were dehydrated and then embedded into paraffin.  
Periodic-acid Shiff diastase resistant (PAS-D) staining was performed on 6µm-thick 
sections of mouse and human livers. This staining marks the glycoprotein, allowing the 
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visualization of ATZ globules in pink. Sections were rehydrated and treated with amylase 
(Sigma) 0.5% for 20 minutes at room temperature (RT) and then stained with PAS reagent 
according to the manufacturer’s instructions (Bio-Optica). Stained liver sections were 
examined under a Leica DM5000 microscope.  
Sirius red staining was performed on 6µm-thick liver sections to mark collagen 
fibers and evaluate hepatic fibrosis. Sections were rehydrated and stained for 1h in picro-
Sirius red solution. After two washes in acidified water (5mL acetic acid glacial in 1L of 
water), the sections were dehydrated in three changes of 100% ethanol, cleared in xylene 
and mounted with a resinous medium. Stained liver sections were examined under a Leica 
DM5000 microscope. The METAVIR scoring system was used to determine the severity 
of hepatic fibrosis and the necro-inflammatory stage as previously described [97]. All 
samples were evaluated by the same pathologist, who was unaware of the laboratory data. 
For immunofluorescence, 5 µm-thick sections were rehydrated by standard 
techniques and permeabilized with PBS, 0.5% Triton. Heat induced epitope retrieval using 
citrate buffer method (pH 6.0) were performed to unmask the antigen sites. The sections 
were then covered for 30 min with 75 mM NH4Cl/PBS to reduce quenching and incubated 
for 1 hour at room temperature with blocking solution [3% bovine serum albumin (BSA; 
Sigma), 5% donkey serum (Millipore), 20 mM MgCl2, 0.3% Triton in PBS pH 7.4]. Then, 
the sections were incubated over night at 4° C with the primary antibodies. The day after, 
sections were washed in PBS and then incubated with the secondary antibodies. Nuclei 
were counterstained with DAPI (Invitrogen).  The secondary antibodies made in donkey 
were: AlexaFluor-594 anti-mouse (Invitrogen) and AlexaFluor-488 anti-rabbit 
(Invitrogen). Finally, the stained liver sections were mounted in mowiol, cover-slipped and 
examined under a Zeiss LSM 700 confocal laser-scanning microscope. The primary 
antibodies used for the immunofluorescence are listed in the table 1. 
Immunofluorescence staining of apoptotic cells was performed by terminal 
deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling 
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(TUNEL) using In Situ Cell Death Detection Kit (Roche Molecular Biochemicals) 
according to the manufacturer’s instructions. Mice injected with 0.5 μg/g of body weight of 
CD95-activating antibody for 6 hours were used as positive control. The image capture 
was performed using Zeiss LSM 700 confocal laser-scanning microscope. The mean area 
and number of the ATZ globules by liver PAS-D staining were quantified using the ImageJ 
plug-in “Analyze particles” on the segmented images. Five different fields of view selected 
randomly for n=3 PiZ and PiZ/Chop-/- mice were used for the quantification. The image 
capture was performed using Leica DM5000 microscope. 
For immunohistochemistry (IHC), 5 µm-thick sections were rehydrated and 
permeabilized in PBS/0.5% Triton (Sigma) for 20 minutes. Antigen unmasking was 
performed in 0.01 M citrate buffer in a microwave oven. Next, sections underwent 
blocking of endogenous peroxidase activity in methanol/1.5% H2O2 (Sigma) for 30 min 
and were incubated with blocking solution [3% BSA (Sigma), 5% donkey serum 
(Millipore), 1.5% horse serum (Vector Laboratories) 20 mM MgCl2, 0.3% Triton (Sigma) 
in PBS] for 1 hour. Sections were incubated with primary antibody (table 1) overnight at 
4°C and with universal biotinylated horse anti-mouse/rabbit immunoglobulin G secondary 
antibody (Vector Laboratories) for 1 hour. Biotin/avidin-horseradish peroxidase signal 
amplification was achieved using the ABC Elite Kit (Vector Laboratories) according to the 
manufacturer’s instructions. 3,30-Diaminobenzidine (Vector Laboratories) was used as 
peroxidase substrate. Mayer’s hematoxylin (Bio-Optica) was used for counterstaining. 
Sections were dehydrated and mounted in Vectashield (Vector Laboratories). Image 
capture was performed using the Leica DM5000 microscope.  
 
3.3 Enzyme-linked immunosorbent assay (ELISA) 
Liver protein extracts and serum samples were analyzed by enzyme-linked 
immunosorbent assay (ELISA) for ATZ detection. Multi-well plates (Nunc Maxisorp) 
were coated with cappel goat anti-human AAT (MP Biomedicals), and then blocked in 
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0.1% PBS Tween 20 containing 5% non-fat milk. Serial dilutions of purified human AAT 
(Athens Research and Technology) were loaded to build a standard curve. Rabbit anti-
human AAT (Dako; 1:4000) was used as capturing antibody and goat anti-rabbit IgG-HRP 
(Dako; 1:2000) as secondary antibody. Then, 100 µL of chromogen substrate o-
Phenylenediamine dihydrochloride (OPD; Sigma) was added to each well and incubated 
for 10 minutes in the dark. The reaction was stopped by adding 50 µL of 3 M H2SO4 to 
each well. The absorbance was measured at 450 nm using the PROMEGA GloMax 
Discover plate reader. In general, for the detection of the ATZ in the liver extracts and 
serum from PiZ mice were used 100 ng of total liver proteins, while the serum was diluted 
1:216 000.  
 
3.4 Real time PCR 
Total RNA was extracted using RNeasy kit (Qiagen) and 1 µg of RNA was reverse 
transcribed using High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). 
PCR reactions were performed using SYBR Green Master Mix (Roche). PCR conditions 
were as follows: pre-heating, 5 min at 95°C; cycling, 40 cycles of 15 sec at 95°C, 15 sec at 
60°C and 25 sec at 72°C. Results were expressed in terms of cycle threshold (Ct). Ct 
values were averaged for each duplicate. β2-microglobulin (B2m) was used as endogenous 
controls. Data were analyzed using LightCycler 480 software, version 1.5 (Roche). Primer 
sequences are listed in table 2.  
 
3.5 Western blotting  
Liver samples homogenized in RIPA buffer with protease and phosphatases 
inhibitors cocktail (Roche) were incubated for 20 min at 4°C and then centrifuged at 
13,200 rpm for 10 min. The pellet was discarded and the supernatant was collected. Protein 
concentrations were measured using Coomassie Plus Bradford assay reagent (Thermo 
Scientific). Samples were denatured and reduced in Laemmli sample buffer containing 
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DTT for 5 min at 100°C and separated by SDS-PAGE. After transfer to PVDF membrane, 
blots were blocked in TBS-Tween20 containing 5% non-fat milk for 1 hour at room 
temperature followed by incubation with the primary antibody overnight at 4°C. Anti-
rabbit IgG or anti-mouse IgG conjugated with horseradish peroxidase (HRP, GE 
Healthcare, 1:3,000) and ECL (Pierce) were used for detection. Primary antibodies used 
for immunoblots are listed in table 1. For the evaluation of protein localization, nuclear 
and cytoplasmic protein extracts were prepared using NXTRACT kit (Sigma-Aldrich) 
according manufacturer’s instructions. In the western blot images, showed in the results 
section, each lane corresponds to an independent mouse. 
 
3.6 Array expression analyses 
Gene expression analysis was performed on 6-week-old male PiZ and C57/BL6 
wild type mice (n=3 per group). All samples were processed on Affymetrix Mouse 430A 
2.0 arrays using GeneChip 3’-IVT Plus and Hybridization Wash and Stain kits by means of 
Affymetrix’s standard protocols. Raw intensity values of the 6 arrays were processed and 
normalized by Robust Multi-Array Average Method [98] using the Bioconductor [99] R 
package Affy [100]. Differentially expressed genes between conditions (PiZ vs. control) 
were identified using a Bayesian T-test [101]. For each p-value, the Benjamini-Hochberg 
procedure was used to calculate the False Discovery Rate (FDR) to avoid the problem of 
multiple testing. The selected gene lists were obtained using the following thresholds: false 
discovery rate (FDR) <0.05 and abs (ratio) >1.5. Data were deposited in GEO with the 
accession number GSE93115. 
 
3.7 Gene Set Enrichment Analysis  
Gene Set Enrichment Analysis (GSEA) [102] was performed using the GSEA 
software (www.broadinstitute.org/gsea). The list of differentially expressed genes between 
PiZ and wild type mouse livers was obtained by expression array profiling described above 
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(GSE93115). The set of CHOP target genes set was defined by combining ChIP-seq and 
RNA-seq data previously reported from tunicamycin-treated wild type mouse embryonic 
fibroblasts [103]. 
 
3.8 Protein co-immunoprecipitation 
HeLa cells were co-transfected with the plasmid expressing CHOP-FLAG and 
plasmids expressing C/EBPβ or c-JUN. Untreated cells and cells co-transfected with the 
plasmid expressing CHOP-FLAG and a plasmid expressing GFP were used as controls. 48 
hours after transfection, cells were washed with PBS and then, protein crosslinking was 
performed using a solution of 1.5 mM dithiobis (succinimidylpropionate) (DSP) (Thermo 
Fisher Scientific) in PBS added to the dishes. The dishes were incubated with DSP for 2 
hours at 4°C. The reaction was stopped with the addition for 15 min at room temperature 
of 1 M Tris, pH 7.8, to a final concentration of 20 mM. The dishes were washed with PBS 
and then lysed as described above. 1 mg of protein lysates was used for the 
immunoprecipitation with mouse anti-FLAG antibody or mouse IgG over night at 4°C. 
The day after, 20 µL of Dynabeads Protein G (Thermo Fisher Scientific) were added to the 
tubes and incubated for 2 hours at 4°C. The flow-through was collected using the magnet 
and the complex Dynabeads-Ab-Ag was washed 5 times using RIPA buffer with 0.1% 
Triton without SDS and 1 time with RIPA buffer without Triton and SDS. Finally, the 
elution was performed by boiling tubes at 100°C for 5 minutes in a solution containing 
SDS 8%. Samples were analyzed by SDS-PAGE as described above. Primary antibodies 
used for immunoprecipitations are listed in table 1. 
 
3.9 Luciferase assays  
For generation of the plasmid with the luciferase gene, human SERPINA1 
regulatory regions were amplified by PCR from genomic DNA of PiZ mice. PCR product 
was cloned into a pGL3-Basic vector (Promega) upstream of the firefly luciferase (pAAT-
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Luc vector). Since SERPINA1 gene has also regulatory regions in the 3’untraslated region 
(UTR), the AAT 3’UTR was cloned downstream the firefly luciferase coding region in the 
pAAT-Luc vector (pAAT-Luc-AAT-3’UTR vector). The cDNA of human c-JUN, CHOP, 
and c-FOS were amplified by RT-PCR from HuH7 cells and cloned into p3xFLAG-CMV-
14 vector. The plasmid expressing human C/EBPβ was purchased from Origene 
(SC319561). AP-1 and CHOP-C/EBPβ heterodimers consensus sequences were 
mutagenized by QuickChange site-directed mutagenesis (Agilent). Primers used for 
generation of the constructs are shown in table 3. HeLa cells were cultured in DMEM in 
10% fetal bovine serum (FBS) and 5% penicillin/streptomycin. Cells were co-transfected 
with the plasmid containing the wild type or mutagenized CHOP-C/EBPβ and AP-1 
consensus sequences and with a plasmid expressing the human CHOP, C/EBPβ, and c-
JUN. Each well was co-transfected with the pRL-TK plasmid (Promega) expressing the 
renilla luciferase as control. Lipo D293 (SigmaGen Laboratories) was used for the DNA 
transfection according to the manufacturer’s instructions. Cells were harvested 48 hours 
after transfection and assayed for luciferase activity using the Dual-Luciferase Reporter 
(DLR™) Assay System (Promega).  Data were expressed relative to renilla luciferase 
activity to normalize for transfection efficiency. Transfections were repeated at least three 
times. 
 
3.10 Chromatin immunoprecipitations (ChIP)  
PiZ mouse livers were mechanically homogenized in PBS in the presence of protein 
inhibitors and then crosslinked by formaldehyde to a final concentration of 1% for 10 
minutes at room temperature. The cross-linking reaction was stopped by the addition of 
glycine at a final concentration of 0.125 mM for 5 minutes at room temperature. After 
three washes in PBS with protein inhibitors, liver homogenates were lysed in cell lysis 
buffer (piperazine-1,4-bis-2-ethanesulfonic acid 5 mM [pH 8.0], Igepal 0.5%, KCl 85 mM) 
for 15 minutes. Nuclei were lysed in lysis buffer (Tris HCl [pH 8.0] 50 mM, ethylene 
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diamine tetra-acetic acid 10 mM, SDS 0.8%) for 30 minutes. Chromatin was sonicated to 
yield DNA fragments approximately 200-1,000 bp. DNA was co-immunoprecipitated 
using the ChIP-grade anti-phospho-c-JUN (Ser73), anti-CHOP, and anti-C/EBPβ 
antibodies overnight at 4°C. No antibody was used in the negative control of the 
immunoprecipitation. Purified immunoprecipitated DNA samples and inputs were 
amplified by quantitative PCR with primers specific for the activator protein 1 (AP-1) and 
the C/EBPβ binding sites of the 5’ untranslated region (5’-UTR) of the SERPINA1 gene. 
Gapdh and Rpl30 promoters were used as negative control regions whereas p62, 
Gabarapl1, and Ctsl1 promoters were used as positive control regions with anti-CHOP and 
anti-C/EBPβ antibodies as previously showed [104, 105]. Antibodies for ChIP and primer 
sequences and are listed in table 1 and 4. 
 
3.11 Human liver samples  
Human liver samples were obtained from the Institute of Pathology, University 
Hospital of Basel (Basel, Switzerland) and St. Louis University School of Medicine, (St. 
Louis, MO, USA). Clinical and pathology features of these samples are shown in tables 5 
The Ethics Committees at each institution approved the study. Human liver samples used 
in Fig. 3 and 10 were collected and anonymized according to applicable human studies 
approvals from subjects homozygous for the p.Glu342Lys mutation in SERPINA1 gene 
and age-matched control subjects homozygous for the wild type allele of SERPINA1 gene. 
PAS-D staining, immunohistochemistry and real-time PCR were performed as for mouse 
studies. Β2M and HPRT1 were used as housekeeping. 
 
3.12 Statistical analyses 
Data are expressed as averages ± standard deviation.  Two tailed Student t test and analysis 
of variance (ANOVA) plus Tukey’s post hoc analysis were used as statistical tests for 
mean comparisons. A p-value<0.05 was considered statistically significant.  
28 
 
Table 1: Primary antibodies and dilutions used.  
 
Antibody Manufacturer WB 
dilution 
IHC 
dilution 
IF 
dilution 
IP 
dilution 
ELISA ChIP 
anti-CHOP Abcam 
(ab11419) 
1/500 1/100 - - - - 
anti-CHOP LifeSpan 
Biosciences 
(LS-B3652) 
- 1/40 - - - - 
anti-GAPDH Santa Cruz 
Biotech 
(sc-365062) 
1/3000 - - - - - 
anti-LAMIN-
A 
Abcam 
(ab26300) 
1/1000 - - - - - 
anti-AAT DAKO 
(A0012) 
- - - - 1/4000 - 
anti-ATZ 
polymer 
Hycult Biotech 
(HM2289) 
- - 1/100 - - - 
anti-FLAG Sigma 
(F1804) 
- - - 1/200 
(3µg) 
- - 
anti-FLAG Sigma 
(F7425) 
1/2000 - - - - - 
anti-C/EBPβ 
 
Abcam 
(ab220813) 
1/1000 - - - - - 
anti-
CALNEXIN 
Enzo Life 
Sciences 
(ADI-SPA-
860) 
1/1000 - - - - - 
IgG mouse Santa Cruz 
Biotech 
(sc-2025) 
- - - 1/80 
(3µg) 
- - 
Anti-CHOP Cell signaling 
(2895) 
- - - - - 1/100 
Anti-C/EBPβ Abcam 
(Ab15050) 
- - - - - 1/200 
Anti-Myc Cell signalling 
(2278) 
1/1000 - - - - - 
Anti-phospho-
c-JUN 
Cell signalling 
(3270) 
1/500 - - - - 1/100 
Anti-c-JUN Cell signalling 
(9165) 
1/500 - - - - - 
Anti-phospho-
JNK1/2 
Cell signalling 
(4668) 
1/500 - - - - - 
Anti-JNK1/2 Cell signalling 
(9252) 
1/500 - - - - - 
Anti-Histone 
H3 
Cell signalling 
(4499) 
1/3000 - - - - - 
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Table 2: Sequence of primers used for qPCR 
Gene Forward (5’-3’) Reverse (5’-3’) 
mChop CACCACACCTGAAAGCAGAA TCCTCATACCAGGCTTCCAG 
mβ2m TGGTGCTTGTCTCACTGACC GTATGTTCGGCTTCCCATTC 
hSERPINA1 TGCCCAGGTATTTCATCAGC CCGTGAAGGTGCCTATGATG 
hCHOP GGAAACAGAGTGGTCATTCCC CTGCTTGAGCCGTTCATTCTC 
hSQSTM1 CAAGTGACATGAAGGGAGGGT ATGTGCTGGGCTGCTAACGTAG 
hATF3 GCTGGAAAGTGTGAATGCTG CTGAGCCCGGACAATACAC 
hTRIB3 GCCTTTTTCACTCGGACCCAT CAGCGAAGACAAAGCGACAC 
hSLC20A1 AGCGTGGACTTGAAAGAGGA TCTTTGTACAGGCCGGAATC 
hALH18A1 GCACACAGCAACCGGATT AGAGCCACGTGGAATGATCA 
hCYB5R1A CATCAGGCCATACACTCCTG GCTATCCAGGTACTGAGACATC 
hMTM1 GCCTTACGCGACGAATACAT GTGAAGTTGGGGGATCAGAAAG 
hLGALS3 CAATTCTGGGCACGGTGAA TGAAGCGTGGGTTAAAGTGG 
hGTPBP2 GAAGGCAGTGGTACGTTTCC GCTTCTCCTGCTGTAATGGC 
hUBE2G2 GAGAAGATCCTGCTGTCGGT TAGAACTGCTCCCGGTCATC 
hHPRT1 CCTGGCGTCGTGATTAGTGAT AGACGTTCAGTCCTGTCCATAA 
 
Table 3: Primers for generation of plasmids used in the luciferase assay and in 
immunoprecipitation studies. 
Gene Forward (5’-3’) 
pAAT-LUC-FW CGGggtaccTGCACTCATCCATTCACTCTGC 
pAAT-LUC-REV CCCaagcttTCTCCAGAACCTCTCGCAGT 
3’UTR-AAT-FW GCtctagaCTGCCTCTCGCTCCTCAAC 
3’UTR-AAT-REV GCtctagaTGCAAGAAATGTAGTTCTATTTATTCTCTG 
c-JUN-FW ATTTgcggccgcATGACTGCAAAGATGGAAACG 
c-JUN-REV CCGgaattcAAATGTTTGCAACTGCTGCG 
AP-1 site1mut-FW CTGGTAGCAAGATCTACCATTTACCAAGCAACCCCAAAATGC
CTGATGCTGAAG 
AP-1 site1mut-REV CTTCAGCATCAGGCATTTTGGGGTTGCTTGGTAAATGGTAGA
TCTTGCTACCAG 
AP-1 site2mut-FW GAGGGGGTGGCGCAAGCAAGACAGTCTCTGGGAGAGTACCA 
AP-1 site2mut-REV TGGTACTCTCCCAGAGACTGTCTTGCTTGCGCCACCCCCTC 
CHOP-FW ATAAGAATgcggccgcATGGAGCTTGTTCCAGCCA 
CHOP-REV CCGgaattcccTGCTTGGTGCAGATTCACC 
c-FOS-FW ATAAGAATgcggccgcATGATGTTCTCGGGCTTC 
c-FOS-REV CCGgaattcccCAGGGCCAGCAGCGTGGGTG 
c-JUN-Myc-FW CCCaagcttATGACTGCAAAGATGGAAACG 
 
c-JUN-Myc-REV CCGgaattcCCAAATGTTTGCAACTGCTGCG 
 
CHOP-C/EBPβ 
site1mut- FW 
CCTTTAAAAGCCTAAATCAGAGGAGATCGCCCGCTGTGCAAC
CCGCA 
CHOP-C/EBPβ 
site1mut- REV 
TGCGGGTTGCACAGCGGGCGATCTCCTCTGATTTAGGCTTTT
AAAGG 
CHOP-C/EBPβ 
site2mut- FW 
GTGGGGCCCCACTTGAGGAGAATCCCTTTAAAAGCCTAAATC
AGATTGCAT 
CHOP-C/EBPβ 
site2mut- REV 
ATGCAATCTGATTTAGGCTTTTAAAGGGATTCTCCTCAAGTG
GGGCCCCAC 
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Small case letters indicate nucleotides used to add restriction enzyme digestion sites. AP-1 
site1mut, AP-1 site2mut, CHOP-C/EBPβ site1mut, and CHOP-C/EBPβ site2mut are the 
primers used for site-directed mutagenesis showed in Fig. 21; mutagenized nucleotides are 
underlined. 
 
Table 4: qPCR primers used for the chromatin immunoprecipitation (ChIP) experiments. 
Gene Forward (5’-3’) Reverse (5’-3’) 
AP-1 sites CGGCAGTAAGTCTTCAGCATC CTGCACTTACCGAAAGGAGTC 
CHOP-
C/EBPβ sites 
TATCTACGGCACGTACGCCA AGGTACAGGGTTGAGGCTAGTG 
p62/Sqstm1 CCTGGTTTTGGCGTTTGTAT GGGATACAGGTCATGAGGATTT 
Gabarapl1 GGCACTTTTCCAACTCCAGA TCCCTCCCCTTCAAGTTTCT 
Ctsl1 AAAATGTGCAGGGTGGAGAG TGTCCTCCGCTCTGTCTTCT 
Gapdh GCCTCAGATCGCTGCTCT GGAGGAAAAGGATGAGATGAG 
Rpl30 CCCTCCATTACCTCAAAGCTG GTACGTGCTGGGCTACAAGC 
 
Table 5: Clinical and pathology features of alpha1-antitrypsin deficiency patients and 
controls. 
Reference Gender Age 
(years) 
Diagnosis 
Control 
#1 
M 41 Focular nodular hyperplasia  
Control 
#2 
F 46 Focular nodular hyperplasia  
Control 
#3 
F 71 Focular nodular hyperplasia  
PiZZ #1 M 90 Chronic hepatitis 
PiZZ #2 M 66 Chronic hepatitis 
PiZZ #3 M 70 Chronic sclerosis steatohepatitis, eosinophil 
infiltration 
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Chapter 4: Results 
To investigate the molecular mechanism underlying the pathogenesis of the disease, 
I used the PiZ mouse model, a transgenic mouse genetically engineered to express the Z 
allele of human SERPINA1 gene under the control of its promoter region. This model has 
been a valuable model for studying the liver disease induced by ATZ and for the 
development of novel therapies. In PiZ mouse livers, ATZ accumulates within the ER of 
hepatocytes as periodic acid Schiff-diastase resistant (PAS-D) positive globules in a nearly 
identical manner to livers of human patients [92]. In addition, in these mice the 
accumulation of ATZ induces liver injury resulting in an inflammatory response, fibrosis 
and increased frequency of HCC [106, 107]. However, because the murine genes for the 
AAT are not mutated, these mice showed normal levels of circulating murine AAT 
proteins and they do not present the lung phenotype.  
Mice have multiple genes encoding AAT and a mouse model deleted for all 
Serpina1 paralogs has been recently generated by using CRISPR/Cas9 genome editing 
[108]. These mice recapitulate the features of human lung disease related to AATD, 
including absence of circulating AAT, reduced capacity to inhibit neutrophil elastase, and 
emphysema. However, as expected this mouse model does not develop a liver disease that 
is due a gain of function mechanism, caused by accumulation of mutant SERPINA1 
variants in the liver.  
 
Section 1: JNK signaling and AATD 
In this section, I will first provide an overview of the roles of c-JUN N-terminal 
kinase (JNK) in physiology and disease states and next I will describe the results we 
recently obtained about the role of JNK in the pathogenesis of liver disease associated to 
AATD. These data have been published in 2017 in the journal “Hepatology” [109].  
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4.1 c-JUN N-terminal kinase (JNK) signaling pathway  
The mitogen-activated protein kinase (MAPK) pathway is an important regulatory 
mechanism, conserved in all eukaryotic cells. The three best characterized subfamilies of 
MAPK proteins are named extracellular signal-regulated kinase (ERK), c-JUN N-terminal 
kinase (JNK), and p38. There are three genes that encode JNK protein kinases in 
mammals: Jnk1, Jnk2 and Jnk3. Among these, Jnk1 and Jnk2 are ubiquitously expressed, 
whereas Jnk3 expression is restricted to the brain, testis and heart [110, 111]. These genes 
are alternatively spliced to create ten isoforms [112]. Transcripts derived from all three 
genes encode protein with and without a C-terminal extention, generating both 46kDa and 
55kDa isoforms. The functional significance of this isoforms is still poorly understood. 
JNK protein kinases are activated by different stress stimuli, including UV irradiation and 
osmotic or oxidative stress. After activation by upstream kinases, they regulate various 
physiological processes in cells, including inflammation, stress, cell growth, cell 
development, differentiation and death [113].  
The activating protein 1 (AP-1) family of transcription factors is among the best 
characterized targets of JNKs. AP-1 family includes structurally and functionally related 
members of the JUN (c-JUN, JUNB and JUND), FOS (c-FOS, FOSB, FRA-1 and FRA-2), 
and ATF (ATF2, ATF3 and ATF7) families. Additionally, new proteins have recently been 
added to the AP-1 family such as MAF proteins (v-MAF and c-MAF) and JUN-dimerizing 
proteins (JDP1 and JDP2) [114, 115].  
A common feature of all these proteins is the evolutionarily conserved bZIP 
domain, composed by a basic DNA-binding domain and leucine zipper domain, 
responsible for dimerization. Like all bZIP transcription factor, AP-1 proteins have to 
dimerize before they can bind to their DNA target sequences. JUN proteins form stable 
homo- and heterodimers, whereas FOS proteins cannot form homodimers. JUN 
homodimers and JUN-FOS heterodimers preferentially bind to the phorbol 12-O-
tetradecanoate-13-acetate (TPA)-responsive element (TRE, consensus sequence: 
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TGACTCA). On the other hand, JUN-ATF heterodimers and ATF homodimers 
preferrentially bind the cAMP-responsive element (CRE, consensus TGACGTCA) [116]. 
Both elements are palindromic and contain the same AP-1 half site.  
JNK proteins are known to phosphorylate c-JUN on two serine residues (amino 
acid positions 63 and 73), leading to its nuclear translocation. JNK-dependent 
phosphorylation of c-JUN increases also its transcriptional activity and stability [117, 118]. 
JNK/c-JUN signaling pathway has been implicated in different biological processes, 
including autophagy, cell differentiation and survival, apoptosis and tumor development 
[113, 114]. In light of its implication in different disease, different drugs targeting JNK/c-
JUN signaling have been developed. One of this is a small molecule named SP600125, 
which inhibits all 3 JNK proteins by competing with the ATP-binding site and results also 
in reduced c-JUN phosphorylation [119].  
 
4.2 The JNK pathway is activated in mouse and human livers expressing ATZ 
To investigate the pathogenesis of liver damage induced by ATZ, we analyzed 
livers of 6-week-old PiZ mice and wild type controls by expression array profiling. 
Analysis of “biological functions” terms indicated that most genes up-regulated in PiZ 
livers were associated with response to unfolded proteins, response to ER stress, ER 
nuclear signaling pathway, and response to protein stimulus (Fig. 1A). Search Tool for the 
Retrieval of Interacting Genes (STRING) analysis that takes into consideration gene-gene 
and protein-protein interactions revealed enrichment of genes induced by cellular response 
to stress, including JNK and c-JUN (Fig. 1B) which have not previously found to be 
affected in livers expressing ATZ.  
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Figure 1: Expression RNA profiling and protein-protein interactions in PiZ mouse livers. 
(A) Genes up-regulated in PiZ mice were associated with the response to unfolded proteins, response to ER, 
ER nuclear signaling pathway, and response to protein stimulus. Livers of 6-week-old PiZ mice (n=3) and 
age-matched and gender-matched controls (n=3) were used for expression array profiling. (B) Search Tool 
for the Retrieval of Interacting Genes analysis showed enrichment on genes of cellular response to stress 
including c-JUN. 
 
We confirmed c-JUN activation by the increased levels of phospho-c-JUN in PiZ mouse 
livers compared to wild type controls (Fig. 2A). C-JUN is one of the main cellular 
substrate activated by JNK through phosphorylation [120] and indeed a significant increase 
of phosphorylated JNK was observed in PiZ mouse livers (Fig. 2B). To investigate the role 
of JNK in vivo, we crossed PiZ mice with Jnk1 or Jnk2 knock-out mice [93, 94]. Being c-
JUN a target of JNK, as expected PiZ/Jnk1-/- and PiZ/Jnk2-/- mice showed reduced hepatic 
phospho-c-JUN/total c-JUN compared to PiZ mice (Fig. 2A, C). Upon phosphorylation c-
JUN translocates to the nucleus where activates its target genes. Consistently with c-JUN 
phosphorylation, we also found increased levels of phospho-c-JUN in the nuclear extracts 
of PiZ mouse livers compared to control wild type mice and compared to either PiZ/Jnk1-/- 
or PiZ/Jnk2-/- mouse livers (Fig. 2D). 
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Figure 2: Activation of the JNK signaling in PiZ mouse livers. 
(A) Western blotting of phosphorylated and total c-JUN in 6-week-old PiZ mouse livers compared to wild 
type (WT) controls and PiZ/Jnk1-/-. (B) Western blotting of phosphorylated and total JNK in 6-week-old PiZ 
mouse livers compared to WT controls. (C) Western blotting of phosphorylated and total c-JUN in 6-week 
old PiZ mouse livers compared to WT controls and PiZ/Jnk2-/-. (D) Western blotting of phosphorylated c-
JUN on nuclear extracts of livers of WT, PiZ, PiZ/Jnk2-/-, and PiZ/Jnk1-/- mouse livers. Nuclear extracts were 
positive for the histone H3 but negative for the cytosolic GAPDH protein. The cytosolic fraction was 
negative for H3 and positive for GAPDH. Abbreviations: GAPDH, glyceraldehyde 3-phosphate 
dehydrogenase; phospho, phosphorylated. 
 
To interrogate the clinical relevance of our findings, we determined whether JNK is 
also activated in human livers from PIZZ patients. Liver samples were obtained from five 
PIZZ patients under 18 years of age homozygous for the p.Glu342Lys mutation in 
SERPINA1 who underwent hepatic transplantation for liver failure. Three control liver 
specimens were obtained from age-matched patients homozygous for the wild type allele 
of SERPINA1 gene who also underwent liver transplantation. As expected, in addition to 
cirrhosis, livers of PIZZ patients showed accumulation of PAS-D positive globules that 
was not detected in control livers (Fig. 3A). Livers of PIZZ patients showed greater 
activation of JNK compared to controls, as shown by increased phosphorylated JNK (Fig. 
3B), thus confirming the findings of activated JNK also in livers of patients with AATD.  
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Figure 3: Activation of the JNK signaling in human livers from PiZZ patients.  
(A) Representative PAS-D staining from a PIZZ patient with cirrhosis who underwent liver transplantation, 
and a control liver from a patient with liver failure due to an unrelated disease (20X magnification, scale bar 
100µm). (B) Western blotting of phosphorylated and total JNK in livers of five PIZZ patients and three 
controls from patients with liver failure due to unrelated diseases. Abbreviation: phospho, phosphorylated. 
 
Taken together these results showed activation of the JNK/c-JUN signaling in mouse and 
human livers expressing ATZ. 
 
4.3 Jnk1 and Jnk2 deletion reduces ATZ accumulation in PiZ mouse livers 
Compared to PiZ, livers of PiZ/Jnk1-/- mice showed reduced ATZ by PAS-D 
staining, immunofluorescence for the polymeric ATZ and ELISA on liver homogenates 
(Fig. 4A, 4B, and 5A).  
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Figure 4: Deletion of Jnk1 and Jnk2 reduces hepatic ATZ accumulation in PiZ mouse livers. 
(A, B) Representative PAS-D staining (upper panels, 20X magnification, scale bar 100µm) and 
immunofluorescence (lower panels, 63X magnification, scale bar 50µm) for the polymeric ATZ on livers of 
PiZ, PiZ/Jnk1-/-, and PiZ/Jnk2-/- mice. 
 
In addition, PiZ/Jnk1-/- mice showed also reduced serum ATZ levels compared to wild type 
control mice (Fig. 5B). 
 
Figure 5: Deletion of Jnk1 and Jnk2 decreases hepatic and serum ATZ levels.  
(A, B) ATZ ELISA on livers and serum of PiZ, PiZ/Jnk1-/- and PiZ/Jnk2-/- mice (at least n=5 per group) 
Averages ± standard deviations are shown. t-test: *p-value< 0.05. 
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SERPINA1 mRNA levels in livers of PiZ/Jnk1-/- mice were also significantly reduced 
compared to PiZ controls (Fig. 6A), suggesting that JNK induces ATZ accumulation by 
increasing SERPINA1 transcription. Like PiZ/Jnk1-/- mice, PiZ/Jnk2-/- mice showed similar 
reductions of ATZ by PAS-D staining (Fig. 4A), immunofluorescence for the polymeric 
ATZ (Fig. 4B), ELISA on the liver extracts and serum (Fig. 5A, B), and real time PCR 
(Fig. 6A) compared to age-matched control wild type mice.  
  
Figure 6: SERPINA1 expression in PiZ, PiZ/Jnk1-/-, and PiZ/Jnk2-/- mouse livers. 
Real time PCR for the SERPINA1 gene in PiZ, PiZ/Jnk1-/-, and PiZ/Jnk2-/- mouse livers (at least n=5 per 
group). β2-microglobulin was used for normalization. Averages ± standard deviations are shown. t-test: *p-
value< 0.05. 
 
4.4 c-JUN regulates SERPINA1 expression 
SERPINA1 gene is transcriptionally regulated at least by two tissue-specific 
regulatory regions located in the 5’-UTR: the liver-specific regulatory region located 
upstream of the non-coding exon 1C and a second regulatory region upstream of exon 1A 
that controls expression in monocytes [28]. The liver-specific regulatory region at the 5’-
UTR contains two putative binding sites for AP-1 [27] that is composed of c-FOS and c-
JUN [27] (Fig. 7A). Therefore, we hypothesized that expression and accumulation of ATZ 
is dependent upon increased JNK-mediated activation of c-JUN and subsequent SERPINA1 
up-regulation. In support of this hypothesis, I found an enrichment of AP-1 binding sites in 
chromatin immunoprecipitates with anti-phosphorylated c-JUN antibody on  PiZ mouse 
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livers (Fig. 7B). Moreover, to further investigate the SERPINA1 regulation, I constructed a 
plasmid including the firefly luciferase gene under the control of the hepatic regulatory 
region at the 5’-UTR of the human SERPINA1 gene including the two putative AP-1 
binding sites (Fig. 7A). HeLa cells co-transfected with this plasmid and a plasmid 
expressing c-JUN showed increased levels of luciferase compared to cells co-transfected 
with the control plasmid (Fig. 7C). The luciferase activity was significantly reduced when 
the one or two binding sites for c-JUN were mutagenized (Fig. 7C). Taken together, these 
results show that c-JUN up-regulates SERPINA1 expression through binding and 
transactivation of the AP-1 sites at the 5’UTR of the SERPINA1. 
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Figure 7: c-JUN regulates SERPINA1 expression. 
(A) Schematic representation of the two putative AP-1 binding sites (consensus sequence 5’-TGACTCA-3’) 
in the 5’-UTR of the SERPINA1 gene (drawn to scale). The hepatocyte regulatory region is located at 
positions –364 (site 1) and –263 (site 2) from the hepatic transcription starting site (TSS)(30) (genomic 
position site 1, chr14:94388968-94388974; site 2, chr14, 94388867-94388873, GRCh38/hg38 assembly). 
Green arrows show the position of the primers used for real-time PCR amplification of the ChIP shown in 
(B). ChIP with anti-phosphorylated c-JUN antibody on PiZ mouse livers showed enrichment of the 5’-UTR 
region containing the two AP-1 binding sites of the SERPINA1 gene. The ChIP results were obtained by three 
independent experiments and are shown as percentage of input. (C) Luciferase activity in HeLa cells co-
transfected with a plasmid containing the human SERPINA1 enhancer regions with two AP-1 putative 
binding sites upstream of the firefly luciferase coding region and plasmid expressing the human c-JUN. 
Experiments were performed in duplicate. Mutagenized constructs co-transfected with c-JUN plasmid were 
compared to non-mutagenized construct co-transfected with c-JUN. Averages ± standard deviations are 
shown. t-test: *p-value< 0.05. Abbreviations: Cyt, cytosolic fraction; 1B, exon 1B; 1C, exon 1C; IP, 
immunoprecipitated DNA; TSS, transcription start site. 
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Section 2: the transcription factor CHOP and AATD 
In this section, I will provide an overview about the function of CHOP and I will 
next describe the results about its role in the pathogenesis of liver disease associated to 
AATD. At the time of the thesis writing, these data presented in this section are being 
submitted to Hepatology. 
 
4.5 The transcription factor CHOP 
CHOP, also known as DNA damage inducible transcript 3 (DDIT3), is a 
transcription factor involved in the ER stress response. Its expression is induced by a 
variety of stress conditions including genotoxic stress, hypoxia, glucose and amino acid 
deprivation, ER stress and unfolded protein response (UPR) [121-125]. First described to 
be involved in ER-stress mediated apoptosis [126], CHOP was found to play a role in 
many other physiological functions such as lipid metabolism, energy metabolism and 
inflammatory response [127, 128]. It is a 29 kDa protein with 169 (human) and 168 
(mouse) amino acid residues, composed by two functional domains: the N-terminal 
activation domain and the C-terminal basic-leucine zipper (bZIP) domain [129]. Under non 
stressed-condition, CHOP is ubiquitously expressed at very low levels and mainly located 
in cytoplasm whereas stress conditions lead to its up-regulation and translocation to the 
nucleus [130]. Its expression is regulated by several transcription factors, including ATF4, 
XBP-1, ATF6, Farnesoid X receptor (FXR), and c-JUN [131-135]. At the post-
transcriptional level, CHOP was found to be phosphorylated on two close serine residues 
by the p38 MAPK [136]. CHOP is implicated in numerous human diseases, such as 
neurodegenerative disease, diabetes, ischemic diseases, tumor, and liver diseases [137-
143]. CHOP is also a positive regulator of autophagy and drives the transcription of several 
autophagy-related genes (Atg), including Atg5, Atg7 and p62/Sqstm1 [104]. 
Considering its implications in different pathological conditions, drug that can inhibit 
CHOP signaling may be therapeutically beneficial. Although some small molecules 
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resulting in CHOP reduction have been developed [144], a specific and efficient drug is 
still lacking.  
 
4.6 CHOP is activated in mouse livers expressing ATZ 
In the expression array profiling on PiZ livers shown in Fig. 1, several up‐regulated 
genes are related to response to ER stress [109]. Among differentially expressed genes, the 
transcription factor CHOP was among the most up-regulated. Compared to age-matched 
wild type controls, Chop showed a significant 12- and 1.9-fold up-regulation in 6- and 36-
week-old PiZ mouse livers, respectively by real time PCR (Fig. 8A). To interrogate the 
clinical relevance of our findings, I also investigated CHOP levels and activation in two 
different sets of livers of PiZZ patients. Compared to controls taken from adult individuals 
with focal nodular hyperplasia, in liver biopsies of three adult PiZZ patients with chronic 
liver disease I detected a 3-fold up-regulation of CHOP mRNA levels (Fig. 8B, Table 5). 
 
Figure 8: CHOP is up-regulated in mouse and human livers expressing ATZ. 
(A) Chop expression in livers of wild type (WT) and PiZ mice of 6 and 36 weeks of age (n=5 per group). β2-
microglobulin  was used for normalization. (B) CHOP expression in liver biopsies from PiZZ patients and 
controls with focal nodular hyperplasia (n=3 per group). β2M and HPRT1 were used for normalization. 
Averages ± standard deviations are shown. t-test: *p-value < 0.05. Abbreviations: 6W, 6-week-old; 36W, 36-
week-old. 
 
Increased expression of CHOP was confirmed at the protein level in 6- and 36-week-old 
PiZ mouse livers (Fig. 9A). Compared to wild type controls, PiZ mouse livers showed 
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increased CHOP levels by western blot also on nuclear extracts at 6-weeks of age, like 
mice injected with tunicamycin, an inducer of ER stress and CHOP expression (Fig. 9B).  
 
Figure 9: CHOP is activated in PiZ mouse livers. 
(A) Western blotting of CHOP in livers of wild type (WT) and PiZ mice of 6 and 36 weeks of age. A liver of 
a WT mouse injected intra-peritoneally with 4 µg/g tunicamycin (TUN) was used as a positive control. (B) 
Western blotting of CHOP on nuclear extracts of 6-week-old WT and PiZ mouse livers. Lamin A was used 
as nuclear marker and GAPDH as cytosolic marker. Abbreviations: 6W, 6-week-old; 36W, 36-week-old; N, 
nuclear extracts; C, cytosolic extracts; TUN, tunicamycin. 
 
Increased nuclear CHOP in PiZ livers was confirmed by immunohistochemistry (IHC) in 
6- and 36-week old PiZ mouse livers (Fig. 10A). In a second set of liver samples from 
PiZZ adults patients with extensive PAS-D staining (Fig. 10B, upper panels) and end-stage 
liver disease requiring liver transplantation [109], increased CHOP nuclear signals was 
detected by IHC compared to controls (Fig. 10B, lower panels). 
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Figure 10: CHOP activation in mouse and human livers expressing ATZ. 
(A) Representative immunohistochemistry (IHC) with anti-CHOP antibody in 6- and 36-week-old wild type 
(WT) and PiZ mouse livers (40X magnification, scale bar 50µm). (B) Representative PAS-D staining (upper 
panels) and IHC with anti-CHOP antibody (lower panels) in liver of PiZZ patients with end-stage liver 
disease underwent to liver transplantation and age-matched PiMM patients who also underwent to liver 
transplantation as controls (20X magnification, scale bar 100µm). 
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Gene Set Enrichment Analysis (GSEA) with microarray expression data (showed in 
Fig. 1A) showed also an enrichment of up-regulated CHOP target genes in PiZ livers 
compared to wild type controls (enrichment score [ES]=0.58) (Fig. 11A). Up-regulation of 
CHOP target genes, selected among the most up-regulated orthologues in PiZ mouse 
livers, was also confirmed by qPCR on human liver biopsies from adult PiZZ patients with 
chronic liver disease and adult controls (Fig. 11B, Table 5). 
 
Figure 11: Up-regulation of CHOP target genes in both mouse and human livers expressing ATZ. 
(A) Heatmap from GSEA using a set of genes up-regulated by CHOP and differentially expressed genes 
between 6-week-old PiZ and wild type (WT) mouse livers. The set of CHOP target genes was defined by 
combining ChIP-seq and RNA-seq data previously reported from tunicamycin treated WT mouse embryonic 
fibroblasts [103]. (B) Heatmap showing the expression of CHOP target genes in human liver biopsies from 
adult PiZZ patients with chronic liver disease and adult controls (n=3 per group; Table 5). β2-
MICROGLOBULIN and HPRT1 were used for normalization. t-test: *p-value<0.05. 
 
 
To further investigate the relationship between ATZ and CHOP activation in liver, 
we injected 4-week-old PiZ mice with a recombinant serotype 8 adeno-associated viral 
(rAAV) vector that incorporates an artificial microRNA (miRNA) targeting the human 
SERPINA1 gene (AAV8-CB-mir914; provided by Dr. C. Mueller, UMass, Boston, USA) 
and results in ATZ knockdown in the liver [145]. As controls, mice were injected with the 
same dose of an AAV8-CB-GFP expressing the green fluorescent protein (GFP). 
Consistent with previous studies [145], mice injected with AAV8-CB-mir914 showed a 
reduction of hepatic ATZ by PAS-D staining (Fig. 12A), and an approximately 90% 
reduction of serum ATZ by 4 weeks post-injection (Fig. 12B). PiZ mice injected with 
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AAV8-CB-mir914 vector also showed a 50% reduction of Chop expression compared to 
mice injected with the control vector (Fig. 12C). Taken together, these data support up-
regulation and activation of CHOP in human and mouse livers expressing ATZ.  
 
Figure 12: CHOP activation correlates with ATZ expression. 
(A) Representative PAS-D staining on livers of PiZ mice injected with 1x1013 genome copies (gs)/Kg of 
recombinant serotype 8 adeno-associated viral (rAAV) vector that incorporate microRNA (miRNA) 
sequences targeting SERPINA1 gene (AAV8-CB-mir914) or green fluorescent protein (GFP) as control 
(AAV8-CB-GFP) (20X magnification, scale bar 100 µm; at least n=5 per group). (B) ELISA for ATZ on 
serum of PiZ mice at the baseline and 4-weeks after the injection of AAV8-CB-mir914 or AAV8-CB-GFP 
vectors. (C) Real time PCR for Chop in livers of PiZ mice injected with AAV8-CB-mir914 or AAV8-CB-
GFP vectors (at least n=5 per group). Averages ± SD are shown. t-test: *p-value < 0.05. Abbreviations: ns, 
not statistically significant; w.p.i, weeks post-injection. 
 
4.7 Juvenile PiZ mice with deleted Chop have reduced hepatic accumulation of ATZ  
To evaluate the role of CHOP in vivo, we crossed CHOP null (Chop-/-) mice [95] 
with PiZ mice. Chop-/- mice do not exhibit a substantial phenotype unless they are 
subjected to stress signals [95]. PiZ mice have reduced weight compared to age- and 
gender-matched wild type controls [146] whereas PiZ/Chop-/- mice showed greater weight 
compared to PiZ mice (Fig. 13A). As previously reported [89], serum ALT levels in PiZ 
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mice were mildly elevated compared to controls, but they were not different from 
PiZ/Chop-/- mice (Fig. 13B). 
 
Figure 13: Alanine transaminase levels and body weight in PiZ and PiZ/Chop-/- mice. 
(A) PiZ and PiZ/Chop-/- mice body weight at different ages (at least n=5 per group). The differences of body 
weights between PiZ and PiZ/Chop-/- mice were statistically significant (Time series analysis; Bayesian 
factor: 5.478). Averages ± SEM are shown. (B) Alanine transaminase (ALT) levels in the serum of 6-week-
old wild type (WT), PiZ and PiZ/Chop-/- mice (n=5 per group). Averages ± standard deviations are shown. 
One-way ANOVA plus Tukey’s post-hoc: *p-value < 0.01. Abbreviations: ns, not statistically significant. 
 
Consistent with previous reports [147], there was no increased apoptosis in PiZ mouse 
livers by TUNEL assay and also PiZ/Chop-/- mice showed no increased apoptosis 
compared to control wild type mice (Fig. 14). 
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Figure 14: Apoptosis in wild type, PiZ and PiZ/Chop-/- mouse livers. 
Representative TUNEL staining in 6-weeks-old wild type (WT), PiZ and PiZ/Chop-/- mouse livers (63X 
magnification, scale bar 50µm; n=3 per group). WT mice treated with 0.5 μg/g of body weight of CD95-
activating antibody for 6 hours were used as positive control of the staining.  
 
Serum ATZ in PiZ/Chop-/- mice was lower compared to PiZ mice at 6 weeks of age 
but no differences were detected in 36-week- and 69-week-old PiZ/Chop-/- compared to 
PiZ controls (Fig. 15A). Targeted qPCR analysis showed down-regulation of SERPINA1 
expression in PiZ/Chop-/- compared to age- and gender-matched 6-week-old PiZ mice and 
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consistent with liver ATZ content, no significant differences in SERPINA1 expression were 
detected in older mice (Fig. 15B). 
 
Figure 15: Deletion of Chop reduces serum ATZ levels and SERPINA1 expression in juvenile PiZ mice. 
(A) ELISA for serum ATZ in PiZ and PiZ/Chop-/- mice of 6, 36, and 69 weeks of age (at least n=4 per 
group). Blood samples were collected from the same mice at different ages. One-way ANOVA plus Tukey’s 
post-hoc: *p<0.05, **p<0.005. (B) SERPINA1 expression in PiZ and PiZ/Chop-/- mice at 6, 36, and 69 weeks 
of age (n=3 per group). β2-Microglobulin was used for normalization. Averages ± standard deviations are 
shown. Two-way ANOVA plus Tukey’s post-hoc: *p<0.05, **p<0.005. Abbreviations: ns, not statistically 
significant; 6W, 6-week-old; 36W, 36-week-old; 69W, 69-week-old. 
 
 
Compared to PiZ, livers of 6-week-old PiZ/Chop-/- mice showed marked reduction of 
hepatic ATZ by PAS-D staining and immunofluorescence with anti-polymer antibody 
(Fig. 16, 17A). However, neither PAS-D staining nor ATZ polymer immunofluorescence 
detected any difference in ATZ accumulation in livers of older 36-week and 69-week-old 
PiZ/Chop-/- mice compared to age-matched PiZ controls (Fig. 16, 17A-C).  
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Figure 16: Genetic ablation of Chop reduces PAS-D positive globules in juvenile PiZ mice. 
Representative PAS-D (20X magnification, scale bar 100µm) staining of livers of PiZ and PiZ/Chop-/- mice 
of 6, 36, and 69 weeks of age. Abbreviations: 6W, 6-week-old; 36W, 36-week-old; 69W, 69-week-old. 
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Figure 17: Genetic ablation of Chop reduces hepatic polymeric ATZ accumulation in PiZ mice. 
(A) Representative immunofluorescence for polymeric ATZ (63X magnification, scale bar 50µm) of livers of 
PiZ and PiZ/Chop-/- mice of 6, 36, and 69 weeks of age. (B-C) Quantification of the mean area (B) and 
number (C) of the ATZ globules in 36-weeks and 69-weeks old PiZ and PiZ/Chop-/- mouse livers visualized 
by PAS-D staining (n=3 per group). Abbreviations: ns, not statistically significant; 6W, 6-week-old; 36W, 
36-week-old; 69W, 69-week-old. 
 
Next, I evaluated the role of CHOP in hepatic fibrosis and hepatocellular carcinoma 
(HCC) induced by ATZ. By real time PCR, I found that expression of genes related to liver 
fibrosis (Cola1a, Timp-1, α-Sma) were not significantly different in livers of 69-weeks old 
PiZ/Chop-/- mice compared to PiZ controls (Fig. 18A). By Sirius red staining, I also did not 
observe any difference in hepatic collagen deposition in 69-weeks old PiZ/Chop-/-mice 
compared to age-matched PiZ controls (Fig. 18B). METAVIR score for the 
histopathological characterization of hepatic fibrosis and necro-inflammatory stage also 
confirmed that Chop deletion did not affect hepatic fibrosis (Fig. 18C, D). 
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Figure 18: Genetic ablation of Chop did not affect hepatic fibrosis due to ATZ accumulation in PiZ 
mice. 
(A) Expression of genes associated to hepatic fibrosis (Col1α1, Timp1, α-Sma) in PiZ and PiZ/Chop-/- mice at 
69 weeks of age (at least n=5 per group). β2-Microglobulin was used for normalization. (B) Representative 
syrius red staining on livers of 69-weeks old PiZ and PiZ/Chop-/- mice (10X magnification, scale bar 200µm). 
(C, D) METAVIR score on hepatic sections from 69-weeks old PiZ and PiZ/Chop-/- mice. Averages 
± standard deviations are shown. Abbreviations: ns, not statistically significant.   
 
 
I also investigated the frequency of HCC in 69-weeks-old PiZ/Chop-/- and PiZ mice. I 
found that 3 out of 13 PiZ mice at 69 weeks of age develop HCC (about 23%) (Fig. 19A-
B), whereas in PiZ/Chop-/- mice we found an incidence of 12.5% (2 out of 16) (Fig. 19A-
B). Although PiZ/Chop-/- mice showed a lower HCC incidence compared to PiZ controls, 
the number of animals used in this experiment is not sufficient to achieve a statistically 
significance and thus, further studies are needed to investigate whether Chop deletion 
reduces the frequency of HCC in PiZ mice.  
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Figure 19: HCC incidence was not affected by Chop deletion in PiZ mice. 
(A) Representative liver photos derived from 69-weeks-old PiZ and PiZ/Chop-/- mice. Tumoral nodules are 
indicated by black arrows. (B) Incidence of liver tumors in 69-weeks-old PiZ and PiZ/Chop-/- mice (n=13 
PiZ, n=16 PiZ/Chop-/-).  
 
To investigate the mechanism underlying reduced accumulation of ATZ in 6-week-
old PiZ/Chop-/- mice, we evaluated protein ubiquitination and LC3-II to rule out the 
involvement of UPS and autophagy. However, no differences were detected between PiZ 
and PiZ/Chop-/- mice (Fig. 20), suggesting that other mechanisms are involved in 
determining different degree of ATZ accumulation.  
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Figure 20: Autophagy marker LC3 and ubiquitin levels are not affected by Chop deletion. 
(A) Western blotting of LC3-I and LC3-II in wild type (WT), PiZ and PiZ/Chop-/-  mouse livers at 6 weeks of 
age. GAPDH was used for normalization. (B) Western blotting of total ubiquitinated proteins in WT, PiZ and 
PiZ/Chop-/- mouse livers at 6 weeks of age. GAPDH was used for normalization. Abbreviations: GAPDH, 
glyceraldehydes 3-phosphate dehydrogenase. 
 
 
Altogether these data suggest that genetic ablation of Chop reduces hepatic ATZ 
accumulation in juvenile PiZ mouse livers. Deletion of Chop did not affect liver fibrosis 
and does not seem to affect significantly the frequency of HCC although further studies 
with larger number of mice are needed to draw a firm conclusion. Finally, these findings 
suggest a role of CHOP in transcriptional regulation of SERPINA1 in juvenile PiZ livers. 
 
4.8 Complexes of CHOP with C/EBPβ or c-JUN up-regulate SERPINA1  
SERPINA1 contains regulatory elements both at 5’ (Fig. 21A) and 3’UTR [30]. The 
5’UTR contains putative binding sites for the AP-1 (in green in Fig. 21A), CHOP-C/EBPβ 
heterodimers (in red in Fig. 21A) and C/EBPβ homodimers (in blue in Fig. 21A) [30]. In 
addition, we also found putative binding sites for C/EBPβ-CHOP heterodimers (in red in 
Fig. 4.21A). CHOP can make stable heterodimers with AP-1 complex (e.g. c-JUN and c-
FOS) and C/EBPβ [148, 149]. To investigate how CHOP regulates SERPINA1 expression, 
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I co-transfected HeLa cells with a plasmid expressing CHOP and the pAAT-Luc-AAT-
3’UTR plasmid that contains the SERPINA1 regulatory elements included in PiZ 
transgenic mice [109] (dashed line in Fig. 21A) upstream the firefly luciferase coding 
region and SERPINA1 3’UTR. As positive control, cells were co-transfected with a 
plasmid expressing c-JUN that transactivates luciferase activity, as previously shown in 
Fig. 7 (Fig. 21B). Compared to cells co-transfected with the negative control, cells co-
transfected with CHOP showed a mild increase in luciferase levels, suggesting that CHOP 
is sufficient to up-regulate SERPINA1 expression (Fig. 21B). In contrast, transfections of 
plasmids expressing c-FOS or C/EBPβ did not increase luciferase activity (Fig. 21B). Co-
transfection of CHOP and c-JUN resulted in greater increase of luciferase levels compared 
to cells transfected with plasmids expressing each of the two transcription factors alone 
(Fig. 21B). Co-transfection of CHOP and C/EBPβ also resulted in greater increase of 
luciferase levels compared to cells transfected with the plasmid expressing CHOP (Fig. 
21B). Mutagenesis of the binding site 2 of the CHOP-C/EBPβ and, at a lower extent, of the 
binding site 1 (in red in Fig. 21A) reduced luciferase activity (Fig. 21C). Mutagenesis of 
the binding site 2 but not site 1 of the AP-1 binding site (in green in Fig. 21A) reduced 
luciferase activity (Fig. 20C). Taken together, these results show that site 2 of the CHOP-
C/EBPβ putative binding site is required for transactivation by CHOP and C/EBPβ and site 
2 of the AP-1 binding site is required for transactivation by CHOP and c-JUN.  
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Figure 21: c-JUN-CHOP and C/EBPβ-CHOP complexes up-regulate SERPINA1 expression.  
(A) Schematic representation of the AP-1 binding sites (1 and 2; in green), putative C/EBPβ-CHOP 
heterodimer binding sites (1 and 2; in red) and putative C/EBPβ binding site (in blue) in the 5’untraslated 
region (UTR) of the SERPINA1 gene (drawn to scale). Nucleotide sequences are shown for the binding sites 
confirmed by luciferase assays: sites 1 and 2 for C/EBPβ-CHOP heterodimer and site 2 for c-JUN-CHOP 
heterodimer. Nucleotide numbering is calculated as distance from the hepatic TSS. Arrows indicate the 
position of the primers for the qPCR on the liver chromatin immunoprecipitates. The dashed line indicates 
the promoter region cloned upstream the luciferase reporter gene in the pAAT-Luc-AAT-3’UTR plasmid. 
Underlined nucleotides have been mutagenized. (B) Luciferase activity in HeLa cells co-transfected with the 
pAAT-Luc-AAT-3’UTR construct and the plasmids expressing human CHOP, C/EBPβ, c-JUN, c-FOS or 
their combinations. An empty CMV-3XFLAG plasmid was used as control. Averages ± standard deviations 
are shown. One-way ANOVA plus Tukey’s post-hoc: a: *p-value < 0.001 vs CMV-3XFLAG; b: *p-
value < 0.0001 vs c-JUN; c: *p-value < 0.0001 vs CHOP. d: *p-value < 0.05 vs CHOP. (C-D) Luciferase 
activity in HeLa cells co-transfected with the pAAT-Luc-AAT-3’UTR construct and with mutagenized sites 
1 and 2 of CHOP-C/EBPβ or AP-1 binding sites and the plasmids expressing human CHOP and C/EBPβ or 
c-JUN. An empty CMV-3XFLAG plasmid was used as control. One-way ANOVA plus Tukey’s post-hoc: 
*p-value < 0.0001 vs site 1WT-2WT CHOP + C/EBPβ (C) or vs 1WT-2WT CHOP + c-JUN (D). Abbreviations: 
ns, not statistically significant; 
 
 
Protein co-immunoprecipitation in HeLa cells co-transfected with a plasmid expressing 
CHOP-FLAG and c-JUN-MYC or C/EBPβ showed that CHOP binds c-JUN (Fig. 22A) 
and all three isoforms of C/EBPβ (LAP*, LAP and LIP) (Fig. 22B) consistent with 
previous studies [149-152]. 
57 
 
 
Figure 22: CHOP co-immunoprecipitates with c-JUN and C/EBPβ.  
(A) HeLa cells were transfected with plasmids expressing CHOP-3XFLAG and c-JUN-MYC fusion proteins 
or control vector (p-CMV-MYC) or left untreated. Cell lysates were immunoprecipitated with anti-FLAG 
antibody and immunoblotted with anti-FLAG antibody to detect CHOP-3XFLAG and anti-MYC antibody to 
detect c-JUN-MYC. Calnexin (CNX) was used as protein loading control. Anti-FLAG immunoblotting 
displayed two bands corresponding the two CHOP isoforms arising from differential translation initiation. 
(B) HeLa cells were transfected with plasmids expressing CHOP-3XFLAG fusion protein and C/EBPβ or 
control vector (pCMV-GFP) or left untreated. Cell lysates were immunoprecipitated with anti-FLAG 
antibody and immunoblotted with anti-FLAG antibody to detect CHOP-3XFLAG and anti-C/EBPβ antibody. 
CNX was used as protein loading control. Anti-FLAG immunoblotting displayed two bands corresponding 
by the two CHOP isoforms arising from differential translation initiation. Abbreviations: CNX, calnexin; IP, 
immunoprecipitates. 
 
To investigate the binding of CHOP, c-JUN and C-EBPβ to SERPINA1 regulatory 
elements, we performed ChIP on PiZ mouse livers with anti-phospho-c-JUN, anti-C/EBPβ, 
or anti-CHOP antibodies. Consistent with findings shown in section 1, enrichment of AP-1 
binding sites (in green in Fig. 23A) was detected in the immunoprecipitates with anti-
phospho-c-JUN antibody whereas no significant enrichment was detected for the putative 
CHOP-C/EBPβ binding sites (in red in Fig. 23A). No enrichment was detected for Gapdh 
promoter region used as negative control (Fig. 23A). In the ChIP with anti-C/EBPβ 
antibody, no enrichment was found for putative CHOP-C/EBPβ binding sites (in red in 
Fig. 23B), AP-1 binding sites (in green in Fig. 23B) and putative C/EBPβ binding sites (in 
blue in Fig. 23B) whereas two positive control regions of Gabarapl1 and Ctsl1 promoters 
were both enriched (Fig. 23B).  
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Figure 23: Chromatin immunoprecipitations in PiZ mouse livers showing the binding of c-JUN on the 
AP-1 binding sites of the SERPINA1 5’UTR. 
(A-B) Chromatin immunoprecipitation (ChIP) on PiZ mouse livers using anti-phospho-c-JUN (A) and anti-
C/EBPβ (B) antibodies followed by qPCR on CHOP-C/EBPβ (in red) and CHOP/c-JUN (in green) putative 
binding sites. Ctsl1 and Gabarapl1 promoter regions were amplified as positive control for C/EBPβ 
enrichment. Gapdh was used as negative control. Averages ± standard deviations are shown. t-test: *p-
value < 0.05. Abbreviations: IP, immunoprecipitated; ns, not statistically significant. 
 
 
Finally, by ChIP with anti-CHOP antibody, CHOP-C/EBPβ binding sites (in red in Fig. 
21A) were significantly enriched in PiZ mouse livers whereas no enrichment was detected 
for AP-1 binding sites (in green in Fig. 21A) (Fig. 24A). As positive control of the ChIP 
with anti-CHOP antibody, p62 promoter region was found to be enriched in PiZ livers 
whereas no signal was detected for the Rpl30 promoter used as negative control. Both 
CHOP-C/EBPβ binding sites and p62 promoter region were not enriched by ChIP with 
anti-CHOP antibody in PiZ/Chop-/- mouse livers (Fig. 24B). Altogether, these results show 
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that CHOP binds the CHOP-C/EBPβ binding sites while phospho-c-JUN binds AP-1 
binding sites in the 5’ UTR region of the SERPINA1 gene. C/EBPβ was not found to 
directly bind the SERPINA1 regulatory regions but protein-protein interactions are lost in 
the ChIP experiment and the luciferase and immunoprecipitation data suggest that C/EBPβ 
forms a complex with CHOP on the CHOP-C/EBPβ binding sites. 
 
Figure 24: CHOP binds the CHOP-C/EBPβ binding sites in the 5’UTR of the SERPINA1. 
(A) Chromatin immunoprecipitations (ChIP) on PiZ mouse livers with anti-CHOP antibody: CHOP/C-EBPβ 
binding sites 1 and 2 were significantly enriched. p62 and Rpl30 promoter regions were used as positive and 
negative controls respectively. (B) Chromatin immunoprecipitations (ChIP) on PiZ/Chop-/- mouse livers with 
anti-CHOP antibody: CHOP/C-EBPβ binding sites 1 and 2, AP-1 binding sites, p62 and Rpl30 promoter 
regions showed no enrichment consistently with the lack of CHOP in these mice. Averages ± standard 
deviations are shown. t-test: *p-value < 0.05. Abbreviations: IP, immunoprecipitated; ns, not statistically 
significant. 
 
Next, I investigated the contribution of each of the two CHOP-C/EBPβ putative 
binding sites in CHOP/c-JUN complex-mediated transactivation of SERPINA1. HeLa cells 
were co-transfected with plasmids expressing CHOP and c-JUN, and with the pAAT-Luc-
AAT-3’UTR plasmid including either the wild type sequences or mutagenized putative 
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CHOP-C/EBPβ binding sites (in red in Fig. 21A). pAAT-Luc-AAT-3’UTR bearing 
mutated CHOP/c-JUN binding sites were transfected as controls. Consistent with the co-
transfection of CHOP and C/EBPβ (Fig. 21C), mutagenized CHOP-C/EBPβ binding site 1 
resulted in moderate but significant reduction of luciferase activity in cells co-transfected 
with CHOP and c-JUN (Fig. 25). Mutagenized site 2 instead completely abolished CHOP 
and c-JUN transactivation (Fig. 25) and resulted in lower luciferase activity compared to 
cells transfected with the pAAT-Luc-AAT-3’UTR plasmid including the wild type 
sequences (Fig. 25). These findings suggest that binding of CHOP to CHOP-C/EBPβ site 2 
(in red in Fig. 21A) is essential for SERPINA1 expression induced by CHOP and c-JUN.  
 
Figure 25: Mutations in the C/EBPβ-CHOP binding sites reduce the CHOP/c-JUN dependent 
transactivation of SERPINA1 expression.  
Luciferase activity in HeLa cells co-transfected with the pAAT-Luc-AAT-3’UTR construct, constructs with 
mutagenized sites 1 and 2 of CHOP-C/EBPβ or AP-1 binding sites and the plasmids expressing human 
CHOP and c-JUN. An empty CMV-3XFLAG plasmid was used as control. Averages ± standard deviations 
are shown. One-way ANOVA plus Tukey’s post-hoc: a: *p-value < 0.001 vs CMV-3XFLAG; b: *p-
value < 0.001 1WT-2WT/1WT-2WT CHOP+c-JUN. Abbreviations: ns, not statistically significant. 
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Chapter 5: Discussion 
JNK signaling in AATD-related liver disease 
The main finding of data presented in section 1 of Chapter 4 is that JNK and c-JUN 
play an important role in liver disease due to toxic accumulation of ATZ by promoting 
SERPINA1 transcriptional up-regulation. I showed that JNK is activated in mouse and 
human livers and being a direct target of JNK1/2, c-JUN regulates SERPINA1 expression. I 
found that the lack of either JNK1 or JNK2 resulted in reduced c-JUN activation and 
SERPINA1 expression, thus reducing hepatic ATZ accumulation.  
Most patients homozygous for the Z mutation never develop clinically relevant 
liver disease. The development of liver injury is thought to require environmental or 
genetic factors that in addition to the Z mutation can reach the threshold for intracellular 
accumulation and toxicity. The results of these studies suggest that JNK is an important 
player which regulates the toxicity of proteotoxic mutant ATZ. 
JNKs are important signaling molecules in multiple pathways in liver physiology 
and diseases. JNK activation affects important biologic functions, such as liver 
regeneration but the same signaling pathway can also be detrimental, such in 
carcinogenesis [153]. The transcription factor c-JUN is a direct target of JNK and was 
found to be activated and increased in the nuclear extracts of PiZ livers. SERPINA1 was 
previously found to contain two putative binding sites for AP-1 [30], composed of c-FOS 
and c-JUN [116]. The luciferase assay in HeLa cells co-transfected with the human c-JUN 
and with the AP-1 consensus sequences of the SERPINA1 and the ChIP study indeed 
confirmed c-JUN trans-activation of SERPINA1 in PIZ mouse livers.  
AAT is an acute-phase protein, controlled by several cytokines, such as IL-6, IL-
1β, TNF-α, oncostatin M or bacterial lipopolysaccharide [30, 154]. Interestingly, c-JUN 
up-regulates IL-6 and TNF-α expression [155, 156] and thus, it can also indirectly increase 
SERPINA1 expression by increasing cytokine levels.  
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Based on the data I generated, factors acting on the JNK pathway such as concomitant 
inflammatory states might further increase SERPINA1 transcription to reach the threshold 
of toxicity for the development of liver disease in AAT deficiency. Additionally, genetic 
modifiers, including those that modulate protein degradation or those that could be directly 
injurious to the liver might be also involved in achieving the toxicity threshold. 
Although its involvement in livers expressing ATZ is controversial [65, 157-159], 
the unfolded protein response can be responsible for JNK activation [111, 160]. 
Nevertheless, the factor(s) activating JNK remains to be investigated. 
The liver disease of AAT deficiency predisposes to HCC [14]. Several clinical and 
experimental studies have implicated stress-activated MAPK cascades that converge on 
JNK and p38 as key regulators of hepatocarcinogenesis [161, 162]. Hepatitis C and 
nonalcoholic steatohepatitis which are predisposing factors for HCC both involve JNK 
activity. JNK1 and JNK2 are phosphorylated in samples from patients with primary HCC 
[163]. JNK1 down-regulates transcription of p21 via c-MYC [163] and c-JUN promotes 
hepatocarcinogenesis by antogonizing p53 activity [164]. Moreover, c-JUN deletion in 
mouse hepatocytes reduces the frequency of HCC [163]. Therefore, our findings of 
activated JNK and c-JUN in livers expressing ATZ are relevant to understand the cancer 
progression in AAT deficiency. 
From a therapeutic perspective, it will be of great importance to understand how 
JNK pathway could be pharmacologically manipulated to improve the liver disease of 
AAT deficiency. We found that inhibition of JNK might have therapeutic potential in 
patients homozygous for the Z mutation. However, JNK molecules play important roles in 
a large number of cellular processes and their inhibition could result in significant side 
effects. Nevertheless, understanding cross-talk among JNK and other pathways activated in 
livers expressing ATZ as well as how these activities are linked with inflammation should 
provide new treatment and prevention strategies. In conclusion, our findings elucidate an 
important pathway involved in the pathogenesis of liver disease in patients homozygous 
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for the Z mutation and highlight novel therapeutic targets.  
 
Role of the transcription factor CHOP in AATD-related liver disease 
Like c-JUN, I have also found that the transcription factor CHOP plays an 
important role in determining the severity of liver disease due to ATZ. It is up-regulated 
and activated in livers of PiZ mice and PiZZ patients and juvenile Chop-deleted mice show 
marked reduction of liver ATZ accumulation. Finally, I found that CHOP is involved in 
regulation of SERPINA1 and I identified the sites of binding of CHOP on SERPINA1 
promoter. 
Although it has been involved in the pathogenesis of several liver disorders [165], the role 
of CHOP in the hepatic disease induced by ATZ has not been yet recognized. CHOP is an 
important player in the unfolded protein response and ER-stress response. Moreover, it is 
activated by several stimuli, such as amino acid and glucose deprivation, DNA damage, 
cellular growth arrest and hypoxia [166]. While the precise factors activating CHOP in 
livers expressing ATZ remain to be identified, we found that CHOP up-regulation plays an 
important role in aggravating ATZ accumulation in juvenile PiZ mice through 
transcriptional up-regulation of SERPINA1 expression. CHOP is a member of the C/EBP 
transcription factors that bind to the CCAAT box motif present in several promoters. It 
includes transcriptional activation/repression domains at its N-terminus and a C-terminus 
bZIP domain that mediates sequence-specific DNA binding and dimerization. Consistent 
with previous studies [148, 150, 152], CHOP was found to form complexes with C/EBPβ 
and c-JUN and these complexes enhanced SERPINA1 expression. I also showed that 
CHOP binds the promoter region and up-regulates SERPINA1 but also greatly enhances c-
JUN-mediated transcriptional up-regulation of SERPINA1. CHOP has indeed a pivotal role 
in SERPINA1 up-regulation because the lack of CHOP binding to SERPINA1 promoter 
greatly diminished SERPINA1 expression induced by c-JUN binding to a distinct site. It 
was previously proposed that CHOP enhances the transcriptional activation of AP-1 by 
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tethering to the AP-1 complex without direct binding of DNA [149]. Our findings suggest 
that transcriptional activation of AP-1 can also occur with binding of CHOP to a site 
located closed to the AP-1 site, because SERPINA1 transcriptional activation was greatly 
diminished when the CHOP/C-EBPβ binding site was mutagenized.  
Previous data showed that CHOP and c-JUN also cooperatively mediate the 
induction of PUMA (p53 up-regulated modulator of apoptosis) during hepatocyte 
lipoapoptosis [167]. More broadly, these data raise the question of whether CHOP 
potentiates c-JUN-mediated transcription in other cell types under different physiologic 
and disease conditions. Interestingly, CHOP is transcriptionally positively regulated by the 
AP-1 complex [135] suggesting a feedback positive loop, in which c-JUN activation up-
regulates CHOP whereas CHOP activation in turn further enhances SERPINA1 expression. 
Such feed-forward mechanism results in ATZ overload and worsening of the liver disease.  
In contrast to older mice, juvenile PiZ mice deleted for Chop showed marked 
reduction of ATZ accumulation suggesting a different role of CHOP at different disease 
stages. Interestingly, levels of blood ATZ in PiZZ patients also appear to decline over time 
[168], a finding that parallels the mouse data shown in this and previous studies [74]. The 
mechanisms underlying the age dependent reduction of CHOP are unknown but the 
reduced load of ATZ due to decreased HNF-4α is a possible explanation [169].  
Clinical data suggest that the human disease has different features in infants 
compared to adults. A survey of large transplantation databases suggested that AAT 
deficiency most commonly causes liver disease requiring liver transplantation in adults, but 
it also revealed that almost all transplant in children were performed under the age of 5 
years [18]. These differences suggest that pathogenetic mechanisms vary depending on the 
age and more powerful modifiers play a role in the liver disease in children [18]. Based on 
my findings, I propose that CHOP and factors regulating its expression might be among 
the modifiers responsible for the more severe disease occurring in the pediatric population. 
Interestingly, CHOP is up-regulated by non-steroidal anti-inflammatory drugs (NSAIDs) 
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[170] and indomethacin given to PiZ mice was previously shown to increase hepatic injury 
and SERPINA1 expression resulting in greater accumulation of ATZ [171]. Moreover, 
exposure of hepatocytes to acetaminophen activates JNK and CHOP and genetic ablation 
of Chop and Jnk2 prevents acetaminophen-induced liver injury [172, 173]. Therefore, 
environmental factors, including drugs, could aggravate ATZ-induced liver injury and 
NSAIDs may be particularly dangerous in children with AAT deficiency.   
There is currently no therapeutic option for children with liver failure due to ATZ 
except for liver transplantation. My studies suggest that inhibition of CHOP might be 
therapeutically relevant in children with severe disease progressing to liver failure and 
requiring liver transplantation.  
Given its recognized role in promoting liver fibrosis and HCC [174-176] which are 
important complications of ATZ-induced liver disease, CHOP might play a role in these 
complications. However, further studies are needed to address these issues.  
In summary, my studies suggest that CHOP is an important player in aggravating 
liver toxicity from abundant accumulation of toxic ATZ in juvenile mice and patients. 
Drugs inhibiting CHOP activity might have potential for therapy of acute liver failure in 
children. 
In conclusion, I propose a model in which hepatocytes expressing ATZ have 
increased activation of JNK/c-JUN and CHOP signaling pathways and as a consequence of 
a feedback positive loop, they further increase SERPINA1 transcription aggravating ATZ 
accumulation (Fig. 26). To address the factors involved in the pathogenesis of the liver 
disease, most studies have been focused on ATZ protein degradation by the ubiquitin-
proteasome system or autophagy [177] whereas the contribution of transcriptional 
regulation of SERPINA1 expression has been neglected. In the livers of subjects carrying 
the Z allele, increased synthesis of ATZ augments the burden of mutant protein and 
proteotoxicity leading to liver disease. Thus, the understanding of factors involved in the 
regulation of SERPINA1 expression in both physiological and pathological conditions is 
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extremely important to identify new therapeutic targets. The findings of my studies might 
ultimate provide new therapeutic and preventive targets for therapy of liver disease due to 
ATZ by elucidation of pathogenic mechanisms affecting SERPINA1 expression during 
liver injury.  
 
 
Figure 26: Graphical summary on the role of JNK and CHOP in the pathogenesis of liver disease due 
to ATZ. 
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